A simple blood draw that could help doctors identify Alzheimer’s disease once sounded like something far in the future.
That future is beginning to arrive.
Blood-based testing has become one of the most closely watched areas of Alzheimer’s research, with scientists studying proteins in the bloodstream that are associated with changes occurring in the brain.
In May 2025, the U.S. Food and Drug Administration cleared the first blood test designed to help identify amyloid pathology associated with Alzheimer’s disease. The test is intended for certain patients experiencing signs of cognitive decline. Research presented at the 2026 Alzheimer’s Association International Conference has taken this discussion further. Scientists found that the blood biomarker p-tau217 may help estimate the risk of cognitive impairment before noticeable memory or thinking problems begin.
For families in White Plains, Westchester County, Manhattan, and the surrounding New York area who are navigating memory concerns, these developments are exciting, but it is equally important to understand what these tests can and cannot currently tell us.
What Are Alzheimer’s Blood Tests Looking For?
Alzheimer’s disease causes or accompanies changes involving brain proteins such as amyloid beta and tau.
Researchers have been developing blood tests capable of measuring biomarkers connected with these changes. One that has received considerable attention is phosphorylated tau 217, often shortened to p-tau217.
The FDA-cleared Lumipulse test measures a combination of p-tau217 and amyloid beta. Doctors can use the results to assess whether amyloid pathology may be present in certain patients experiencing cognitive decline. However, the test cannot diagnose Alzheimer’s disease on its own.
That distinction matters.
Memory changes can have many causes, which is why cognitive concerns should be evaluated comprehensively rather than reduced to the result of a single test.
New Research Is Looking Even Earlier
One of the most interesting developments came from research presented at the Alzheimer’s Association International Conference in July 2026.
A real-world study presented at the 2026 Alzheimer’s Association International Conference involved 1,310 patients and 165 physicians. Access to blood biomarker results significantly improved Alzheimer’s diagnostic accuracy among specialists and primary care physicians.
Among participants with very high p-tau217, researchers reported an approximately 78% risk of cognitive impairment over ten years. The authors emphasized that further verification is needed before this type of testing could be routinely used to predict an individual’s future.
Other NIH-supported research has also found associations between Alzheimer’s-related blood biomarkers and cognitive performance during midlife, further demonstrating why scientists are so interested in what blood may eventually reveal about brain changes occurring years before dementia becomes apparent.
Does This Mean Everyone Should Get an Alzheimer’s Blood Test?
No.
The FDA specifically states that the currently cleared Lumipulse test is not intended as a general screening test or a stand-alone diagnostic test. Doctors use it alongside a clinical evaluation for people showing signs or symptoms of cognitive decline.
That is an important distinction between what is available clinically today and what researchers are investigating for tomorrow.
For now, someone concerned about changes in memory, reasoning, language, personality, or the ability to complete familiar tasks should begin by speaking with a qualified healthcare professional.
The most exciting part of blood biomarker research may ultimately be accessibility. Traditional Alzheimer’s evaluation can sometimes require specialized imaging or spinal fluid testing. Researchers are examining whether blood tests could make high-quality evaluation more widely available and help doctors determine which patients need additional testing or specialist care.
Researchers presented a real-world study involving more than 1,300 patients at the 2026 Alzheimer’s Association International Conference. Blood biomarker results significantly improved diagnostic accuracy among specialists and primary care physicians.
Earlier Answers Could Help Families Plan Earlier
An Alzheimer’s diagnosis affects much more than medicine.
It affects housing, caregiving, finances, family relationships, safety, and decisions about the future.
Earlier and more accessible evaluation could eventually give families more time to understand what is happening and consider the appropriate next steps.
For families searching for memory care near Manhattan or throughout Westchester County, including White Plains, Scarsdale, Rye, and nearby communities, that planning period can be invaluable.
The goal should not simply be finding “a place” after a crisis occurs. It should be identifying an environment capable of adapting as someone’s cognitive and physical needs evolve.
Memory Care That Preserves the Person Behind the Diagnosis
The Kensington White Plains organizes memory care around each resident’s level of need.
Connections supports residents in the early to middle stages of memory loss who retain greater independence. Haven supports residents experiencing more advanced dementia and greater assistance needs. The community’s stated approach is to provide help where necessary while continuing to encourage residents to use their remaining abilities and participate meaningfully in everyday life.
Residents have access to licensed nursing around the clock, medication support, and rehabilitation services. Visiting physicians and specialists provide additional support, while purposeful programming promotes communication and engagement.
A diagnosis may change what someone needs.
It should not change how much their preferences, history, relationships, interests, and moments of joy matter.
Looking Toward the Future of Alzheimer’s Care
The science surrounding Alzheimer’s disease is changing quickly.
Blood tests will not replace thoughtful clinical evaluation, nor can a laboratory result tell a family exactly what the years ahead will look like.
But the ability to identify Alzheimer’s-related changes more easily and potentially earlier represents a meaningful step forward.
And for families, earlier knowledge can create something extremely valuable: time.
This additional time allows families to ask questions, make plans, find the right support, and focus on helping their loved one continue living a meaningful life throughout every stage of the journey